Sanofi's Bispecific Lunskeimig Succeeds in Asthma and Sinusitis Phase 2 Trials, Falls Short in Eczema

on

Sanofi's lunsekimig, a bispecific antibody targeting IL-13 and TSLP, met primary and key secondary endpoints in the phase 2b AIRCULES trial for moderate-to-severe asthma, showing significant reduction in exacerbations and improved lung function.123

In the phase 2a DUET trial for chronic rhinosinusitis with nasal polyps (CRSwNP), lunsekimig met its primary endpoint of change in nasal polyp score and key secondary endpoints for nasal congestion and CT scores at week 24.123

The phase 2b VELVET trial in moderate-to-severe atopic dermatitis missed its primary endpoint, though improvements were seen in secondary skin clearance measures; this was an exploratory indication.123

Lunsekimig was generally well-tolerated across all studies, with safety profiles similar to placebo and common adverse events like nasopharyngitis and headache.23

Results announced April 7, 2026; Sanofi plans phase 3 trials in respiratory diseases like COPD.12

Sources:

1. https://pharmaphorum.com/news/sanofis-bispecific-lunsekimig-has-mixed-readouts-phase-2

2. https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-07-05-00-00-3268809

3. https://www.fiercebiotech.com/biotech/sanofis-bispecific-scores-double-respiratory-phase-2-wins-flunks-eczema-study-0